BR112021015238A2 - Novos anticorpos de ligação a cd40 - Google Patents
Novos anticorpos de ligação a cd40Info
- Publication number
- BR112021015238A2 BR112021015238A2 BR112021015238A BR112021015238A BR112021015238A2 BR 112021015238 A2 BR112021015238 A2 BR 112021015238A2 BR 112021015238 A BR112021015238 A BR 112021015238A BR 112021015238 A BR112021015238 A BR 112021015238A BR 112021015238 A2 BR112021015238 A2 BR 112021015238A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding
- antibodies
- new
- binding antibodies
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
novos anticorpos de ligação a cd40. a presente invenção se refere a novos anticorpos capazes de se ligar a cd40 humano e a novos anticorpos multiespecíficos capazes de se ligar a cd40 humano e de se ligar a um receptor de células t v¿9v¿2 humano. a invenção também se refere a composições farmacêuticas que compreendem os anticorpos da invenção e aos usos dos anticorpos da invenção para tratamento médico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2022494A NL2022494B1 (en) | 2019-02-01 | 2019-02-01 | Novel CD40-binding antibodies |
NL2024087 | 2019-10-23 | ||
PCT/NL2020/050051 WO2020159368A1 (en) | 2019-02-01 | 2020-01-30 | Novel cd40-binding antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112021015238A2 true BR112021015238A2 (pt) | 2022-02-15 |
BR112021015238A8 BR112021015238A8 (pt) | 2022-08-16 |
Family
ID=71840475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021015238A BR112021015238A8 (pt) | 2019-02-01 | 2020-01-30 | Novos anticorpos de ligação a cd40 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220135694A1 (pt) |
EP (1) | EP3917960A1 (pt) |
JP (1) | JP2022519082A (pt) |
KR (1) | KR20210141466A (pt) |
CN (1) | CN113993893A (pt) |
AU (1) | AU2020216250A1 (pt) |
BR (1) | BR112021015238A8 (pt) |
CA (1) | CA3128148A1 (pt) |
MX (1) | MX2021009285A (pt) |
SG (1) | SG11202108141VA (pt) |
WO (1) | WO2020159368A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI4010082T1 (sl) | 2020-08-14 | 2023-04-28 | GammaDelta Therapeutics Limited, | Multispecifična protitelesa anti-TCR delta variable 1 |
EP4259660A1 (en) * | 2020-12-10 | 2023-10-18 | LAVA Therapeutics N.V. | Antibodies that bind gamma-delta t cell receptors |
TW202246338A (zh) * | 2021-02-17 | 2022-12-01 | 英商適應生物治療有限公司 | 抗TCRδ可變1抗體 |
WO2022263855A1 (en) | 2021-06-18 | 2022-12-22 | Autolus Limited | Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases |
WO2023025194A1 (zh) * | 2021-08-24 | 2023-03-02 | 江苏恒瑞医药股份有限公司 | Fap/cd40结合分子及其医药用途 |
WO2023067138A1 (en) | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
WO2023133394A1 (en) * | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-binding polypeptides and uses thereof |
CA3208653A1 (en) * | 2022-02-17 | 2022-08-25 | Mihriban Tuna | Multispecific anti-tcr delta variable 1 antibodies |
EP4292609A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7288252B2 (en) * | 2000-10-02 | 2007-10-30 | Novartis Vaccines And Diagnostics, Inc. | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
KR20110134494A (ko) | 2009-03-27 | 2011-12-14 | 자이모제네틱스, 인코포레이티드 | 항체-수용체 조합물을 포함하는 다중특이적-결합 단백질을 사용하기 위한 조성물 및 방법 |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
PT2838918T (pt) | 2012-04-20 | 2019-08-23 | Merus Nv | Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig |
JP6144771B2 (ja) | 2012-11-21 | 2017-06-07 | ファームアブシン インコーポレイテッド | Vegfr−2とdll4を標的とする二重標的抗体及びこれを含む薬学的組成物 |
SG10202007233TA (en) | 2014-04-10 | 2020-09-29 | Lava Therapeutics B V | IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS |
-
2020
- 2020-01-30 EP EP20703313.5A patent/EP3917960A1/en active Pending
- 2020-01-30 AU AU2020216250A patent/AU2020216250A1/en active Pending
- 2020-01-30 BR BR112021015238A patent/BR112021015238A8/pt unknown
- 2020-01-30 CN CN202080018185.2A patent/CN113993893A/zh active Pending
- 2020-01-30 MX MX2021009285A patent/MX2021009285A/es unknown
- 2020-01-30 JP JP2021544622A patent/JP2022519082A/ja active Pending
- 2020-01-30 KR KR1020217027592A patent/KR20210141466A/ko unknown
- 2020-01-30 CA CA3128148A patent/CA3128148A1/en active Pending
- 2020-01-30 WO PCT/NL2020/050051 patent/WO2020159368A1/en unknown
- 2020-01-30 US US17/427,291 patent/US20220135694A1/en active Pending
- 2020-01-30 SG SG11202108141VA patent/SG11202108141VA/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113993893A (zh) | 2022-01-28 |
KR20210141466A (ko) | 2021-11-23 |
US20220135694A1 (en) | 2022-05-05 |
BR112021015238A8 (pt) | 2022-08-16 |
CA3128148A1 (en) | 2020-08-06 |
EP3917960A1 (en) | 2021-12-08 |
MX2021009285A (es) | 2021-11-12 |
SG11202108141VA (en) | 2021-08-30 |
AU2020216250A1 (en) | 2021-08-26 |
JP2022519082A (ja) | 2022-03-18 |
WO2020159368A1 (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021015238A2 (pt) | Novos anticorpos de ligação a cd40 | |
BR112018010018A2 (pt) | moduladores de ror-gama | |
BR112018015603A2 (pt) | ?conjugado de enzimas terapêuticas, seu método de preparação, composição farmacêutica, composição para aumentar a transcitose e seu método, composição para aumentar a distribuição de tecido de uma enzima e seu método? | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
BR112017007460A2 (pt) | inibidores de di-hidropirrolopiridina de ror-gama | |
BR112014027204A2 (pt) | conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos | |
BRPI1008145B8 (pt) | Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica | |
DOP2016000156A (es) | Composiciones farmacã¿uticas que comprenden azd9291. | |
BR112015014372A8 (pt) | inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas". | |
BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
BR112019024747A2 (pt) | formulações de dose fixa | |
BR112022007612A2 (pt) | Inibidores de raf quinases | |
BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
BR112018069930A2 (pt) | agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos | |
BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
CL2019001586A1 (es) | Insulina que contiene composiciones farmacéuticas. | |
MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
BR112017022757A2 (pt) | derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap) | |
EA201991951A1 (ru) | Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения | |
CL2020002957A1 (es) | Biarilamidas con grupos de azúcar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteína de choque de calor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: LAVA THERAPEUTICS N.V. (NL) |